What exact doses and brand names (with generic names) of transdermal estrogen and progestogen should be prescribed for a healthy 53‑year‑old postmenopausal woman with an intact uterus to ensure continuous endometrial protection?

Recommended Transdermal Hormone Therapy Regimen

For a healthy 53-year-old postmenopausal woman with an intact uterus, prescribe transdermal estradiol 50 mcg/day combined with either transdermal norethisterone acetate (NETA) 140-170 mcg/day or oral micronized progesterone 100 mg daily for continuous combined therapy to ensure endometrial protection. 1

Specific Transdermal Estrogen Options

Start with transdermal estradiol 50 mcg/day delivered via:

• Transdermal patch (applied twice weekly)
• Percutaneous gel (daily application)
• Transdermal spray (daily application)

The 50 mcg dose provides effective symptom relief while minimizing systemic effects. Transdermal delivery avoids first-pass hepatic metabolism, reducing risks of venous thromboembolism, increases in triglycerides, inflammatory markers (C-reactive protein), and binding globulins compared to oral estrogens 2. This route is particularly advantageous for women with VTE risk, hypertension, hypertriglyceridemia, obesity, metabolic syndrome, diabetes, or gallbladder disease history 2.

Progestogen for Endometrial Protection

Option 1: Transdermal Combination Patches (Preferred for Simplicity)

Brand names with transdermal estradiol-progestogen combinations:

• Estradiol 50 mcg + norethisterone acetate (NETA) 140-170 mcg - Applied twice weekly continuously 1, 3
• Estradiol 50 mcg + levonorgestrel 0.075 mg - Applied continuously 1

These fixed-dose combination patches provide proven endometrial protection with no cases of hyperplasia or cancer reported in 96-week studies 4. The lower NETA dose (140-170 mcg) is sufficient for endometrial safety 3.

Option 2: Separate Oral Progestogen (If Transdermal Progestogen Unavailable)

If using transdermal estradiol gel or spray without a combination patch, add oral micronized progesterone 100 mg daily for continuous combined therapy 1. This provides adequate endometrial protection while potentially offering a more favorable breast cancer risk profile compared to synthetic progestogens 1.

Alternative oral progestogens for continuous combined regimens:

• Medroxyprogesterone acetate (MPA) 2.5 mg daily
• Norethisterone acetate 0.35 mg daily
• Drospirenone 3 mg daily 1

Continuous vs. Sequential Regimens

Use continuous combined therapy (estrogen + progestogen daily without breaks) for this 53-year-old woman to achieve amenorrhea and maximize compliance 1. Sequential regimens (progestogen 12-14 days/month) typically cause monthly withdrawal bleeding, which is the primary reason for treatment discontinuation 1.

Continuous combined therapy with transdermal NETA produces progestational atrophy in 66-84% of women, providing robust endometrial protection 3. Expect breakthrough bleeding in some women initially, but most achieve amenorrhea within 3-6 months 4.

Critical Endometrial Safety Points

• Never use estrogen alone in women with an intact uterus - this causes endometrial hyperplasia and cancer 2, 1
• Progestogen must be given for at least 12-14 days monthly in sequential regimens or daily in continuous regimens 5
• Lower doses or shorter durations increase risks of breakthrough bleeding, hyperplasia, and malignancy 5
• Any unexpected vaginal bleeding requires immediate endometrial evaluation with ultrasound and biopsy 1

Monitoring and Adjustments

• Start with the lowest effective dose and titrate based on symptom control 1
• Do not use serum FSH levels to monitor adequacy - they remain elevated despite adequate tissue effects 1
• If progestogen side effects occur (mood changes, bloating, sleep disturbance), switch to a different progestogen rather than reducing dose 1
• Consider vaginal progesterone gel (45 mg twice weekly) as an alternative if oral/transdermal progestogens are poorly tolerated, though this is less well-studied 6

Important Caveats

Avoid custom-compounded "bioidentical" hormones - they lack FDA oversight and have no proven endometrial protection data 2. Use only FDA-approved formulations that are biochemically identical to endogenous hormones (17β-estradiol and micronized progesterone) 2.

The levonorgestrel intrauterine device provides endometrial protection with minimal systemic absorption, but observational data suggest increased breast cancer risk (OR 2.15 when combined with estradiol) 1.